- Home
- EOLS vs ERAS Comparison
EOLS vs ERAS Comparison
Compare EOLS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOLS
- ERAS
- Stock Information
- Founded
- EOLS 2012
- ERAS 2018
- Country
- EOLS United States
- ERAS United States
- Employees
- EOLS N/A
- ERAS N/A
- Industry
- EOLS Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- EOLS Health Care
- ERAS Health Care
- Exchange
- EOLS Nasdaq
- ERAS Nasdaq
- Market Cap
- EOLS 406.9M
- ERAS 439.7M
- IPO Year
- EOLS 2018
- ERAS 2021
- Fundamental
- Price
- EOLS $6.50
- ERAS $2.42
- Analyst Decision
- EOLS Strong Buy
- ERAS Buy
- Analyst Count
- EOLS 4
- ERAS 6
- Target Price
- EOLS $21.25
- ERAS $3.83
- AVG Volume (30 Days)
- EOLS 1.0M
- ERAS 1.7M
- Earning Date
- EOLS 11-05-2025
- ERAS 11-11-2025
- Dividend Yield
- EOLS N/A
- ERAS N/A
- EPS Growth
- EOLS N/A
- ERAS N/A
- EPS
- EOLS N/A
- ERAS N/A
- Revenue
- EOLS $277,941,000.00
- ERAS N/A
- Revenue This Year
- EOLS $13.68
- ERAS N/A
- Revenue Next Year
- EOLS $27.96
- ERAS N/A
- P/E Ratio
- EOLS N/A
- ERAS N/A
- Revenue Growth
- EOLS 17.15
- ERAS N/A
- 52 Week Low
- EOLS $5.71
- ERAS $1.01
- 52 Week High
- EOLS $17.82
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- EOLS 44.82
- ERAS 73.72
- Support Level
- EOLS $6.08
- ERAS $1.78
- Resistance Level
- EOLS $6.36
- ERAS $2.35
- Average True Range (ATR)
- EOLS 0.22
- ERAS 0.20
- MACD
- EOLS 0.04
- ERAS 0.05
- Stochastic Oscillator
- EOLS 71.96
- ERAS 78.67
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.